[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-406362-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-406362-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","tepotinib-in-patients-with-non-small-cell-lung-cancer-with-high-level-met-amplification-detected-by-liquid-biopsy-vision-cohort-b","Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy - VISION Cohort B","","High-level MET amplification (METamp) drives a small fraction of non-small cell lung cancers, and liquid biopsy can identify these patients for targeted therapy. In VISION trial Cohort B, tepotinib, an oral MET inhibitor, was assessed in 24 enrolled patients with advanced NSCLC and high-level METamp. Despite halting before planned enrollment, tepotinib demonstrated antitumor activity with objective response rate (ORR) 41.7% and median duration of response 14.3 months. Safety showed mainly mild-to-moderate adverse events without new signals, and exploratory biomarkers correlated with outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/tepotinib-in-patients-with-non-small-cell-lung-cancer-with-high-level-met-amplification-detected-by-liquid-biopsy-vision-cohort-b/406362/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/tepotinib-in-patients-with-non-small-cell-lung-cancer-with-high-level-met-amplification-detected-by-liquid-biopsy-vision-cohort-b/406362.png","ImageObject",300,407,{"name":42,"@type":43},"Mary Man","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-05","2026-09-28",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the purpose of VISION Cohort B?","Question",{"text":63,"@type":64},"VISION Cohort B evaluates tepotinib in patients with advanced non-small cell lung cancer identified as having high-level MET amplification by liquid biopsy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What efficacy results were reported for tepotinib?",{"text":68,"@type":64},"Tepotinib showed an objective response rate (ORR) of 41.7% and a median duration of response of 14.3 months.",{"name":70,"@type":61,"acceptedAnswer":71},"What adverse events were highlighted in the safety results?",{"text":72,"@type":64},"Adverse events included edema (any grade 58.3%; grade 3 12.5%) and constipation (any grade 41.7%; grade 3 4.2%).","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},406362,1792123309,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":4},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Article  \nTepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B  \nAuthors  \nXiuning Le, Luis G. Paz-Ares, Jan Van Meerbeeck, ..., Gordon Otto, Andreas Johne, Paul K. Paik  \nCorrespondence  \n[xle1@mdanderson.org](xle1@mdanderson.org)  \nIn brief  \nHigh-level METamplification (METamp) is a primary driver in 􀀁 1%–2% of non-small cell lung cancers (NSCLCs) . Le et al. report that tepotinib provides antitumor activity in patients with high-level METamp NSCLC in VISION trial Cohort B. Tepotinib is a promising option for these patients, who urgently require new treatments.  \nd High-level MET amplification (METamp) is a primary driver in  \n􀀁 1%–2% of NSCLCs  \nd VISION Cohort B evaluates tepotinib in 24 patients with highlevel METamp NSCLC  \nd Tepotinib shows antitumor activity: ORR is 41.7%, and median DOR is 14.3 months  \nd Safety is manageable, with mostly mild/moderate AEs and no new safety signals  \nLe et al., 2023, Cell Reports Medicine 4, 101280 November 21, 2023 ª 2023 The Authors.  \n[https://doi.org/10.1016/j.xcrm.2023.101280](https://doi.org/10.1016/j.xcrm.2023.101280)  \nll  \nll  \nOPEN ACCESS  \nArticle  \nTepotinib in patients with non-small cell lung cancer with high-level METamplification detected by liquid biopsy: VISION Cohort B  \nXiuning Le,1,* Luis G. Paz-Ares,2 Jan Van Meerbeeck,3 Santiago Viteri,4,26 Carlos Cabrera Galvez,5 Egbert F. Smit,6,27 Marina Garassino,7 Remi Veillon,8 David Vicente Baz,9 Jose Fuentes Pradera,10 Mara Sereno,11 Toshiyuki Kozuki,12 Young-Chul Kim,13 Seung Soo Yoo,14 Ji-Youn Han,15 Jin-Hyoung Kang,16 Choon-Hee Son,17 Yoon Ji Choi,18 Christopher Stroh,19 Dilafruz Juraeva,20 Helene Vioix,21 Rolf Bruns,22 Gordon Otto,23 Andreas Johne,23,28  \nand Paul K. Paik24,25  \n1Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA  \n2Department of Medical Oncology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain  \n3Department of Thoracic Oncology, Antwerp University Hospital (UZA), 2650 Edegem, Belgium  \n4Instituto Oncologico Dr. Rosell, Hospital Universitari Dexeus, Grupo QuironSalud, 08028 Barcelona, Spain  \n5Department of Medical Oncology, Hospital Universitari Sagrat Cor, 08029 Barcelona, Spain  \n6Department of Thoracic Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands  \n7Department of Medicine, Section of Hematology/Oncology, Knapp Center for Biomedical Discovery, The University of Chicago, Chicago, IL 1084250, USA  \n8CHU Bordeaux, Service des Maladies Respiratoires, 33000 Bordeaux, France  \n9Department of Medical Oncology, Hospital Universitario Virgen Macarena, 41009 Seville, Spain  \n10Department of Medical Oncology, Hospital Universitario Nuestra Se˜nora de Valme, 41014 Seville, Spain  \n11Department of Medical Oncology, Hospital Universitario Infanta Sofia, San Sebasti´an de los Reyes, 28703 Madrid, Spain  \n12Department of Respiratory Medicine, NHO Shikoku Cancer Center, Matsuyama City 791-0280, Japan  \n13Department of Internal Medicine, Chonnam National University Medical School and CNU Hwasun Hospital, Hwasun-Gun 58128, Rep. of Korea  \n14Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu 41566, Rep. of Korea  \n15The Center for Lung Cancer, National Cancer Center, Goyang 10408, Rep. of Korea  \n16Division of Medical Oncology, The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul 06591, Rep. of Korea  \n17Department of Internal Medicine, Dong-A University, 840 Hadan 2-dong, Saha-gu, Busan 604-714, Rep. of Korea  \n18Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital, Seoul 02841, Rep. of Korea  \n19Clinical Biomarkers & Companion Diagnostics, the healthcare business of Merck KGaA, 64293 Darmstadt, Germany  \n20Oncology Bioinformatics, the healthcare business of Merck KGaA, 64293 Darmstadt, German","cbCaincjDvXZKhM9","https://ap.wps.com/l/cbCaincjDvXZKhM9","pdf",3490101,15,"English","# In brief\n## Study objective and population\n## Efficacy outcomes\n## Safety and adverse events\n## Exploratory biomarker findings","[{\"question\":\"What is the purpose of VISION Cohort B?\",\"answer\":\"VISION Cohort B evaluates tepotinib in patients with advanced non-small cell lung cancer identified as having high-level MET amplification by liquid biopsy.\"},{\"question\":\"What efficacy results were reported for tepotinib?\",\"answer\":\"Tepotinib showed an objective response rate (ORR) of 41.7% and a median duration of response of 14.3 months.\"},{\"question\":\"What adverse events were highlighted in the safety results?\",\"answer\":\"Adverse events included edema (any grade 58.3%; grade 3 12.5%) and constipation (any grade 41.7%; grade 3 4.2%).\"}]","Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy - VISION Cohort B | PDF",1790565131,38]